Spark Therapeutics Inc. (NASDAQ:ONCE) CEO Jeffrey D. Marrazzo sold 10,000 shares of Spark Therapeutics stock in a transaction on Friday, September 16th. The stock was sold at an average price of $62.68, for a total transaction of $626,800.00. Following the transaction, the chief executive officer now directly owns 240,000 shares of the company’s stock, valued at $15,043,200. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Spark Therapeutics Inc. (NASDAQ:ONCE) opened at 64.71 on Wednesday. The firm’s market cap is $1.98 billion. Spark Therapeutics Inc. has a 52 week low of $21.20 and a 52 week high of $66.00. The firm’s 50-day moving average price is $58.88 and its 200 day moving average price is $47.34.

Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings data on Wednesday, August 10th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by $0.07. The business earned $1.29 million during the quarter, compared to the consensus estimate of $1.17 million. Spark Therapeutics had a negative net margin of 366.76% and a negative return on equity of 26.96%. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.60) EPS. Equities analysts forecast that Spark Therapeutics Inc. will post ($3.96) earnings per share for the current fiscal year.

A number of research firms have commented on ONCE. Zacks Investment Research cut shares of Spark Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 16th. Wedbush reissued an “underperform” rating and set a $29.00 target price (up previously from $28.00) on shares of Spark Therapeutics in a report on Wednesday, August 10th. Cantor Fitzgerald reissued a “buy” rating and set a $94.00 target price on shares of Spark Therapeutics in a report on Thursday, August 11th. Jefferies Group reissued a “hold” rating on shares of Spark Therapeutics in a report on Friday, August 5th. Finally, Stifel Nicolaus began coverage on Spark Therapeutics in a report on Friday, September 2nd. They set a “buy” rating and a $73.00 target price for the company. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $62.27.

A number of hedge funds and other institutional investors have recently made changes to their positions in ONCE. Quantbot Technologies LP acquired a new position in shares of Spark Therapeutics during the second quarter worth about $124,000. Teacher Retirement System of Texas increased its position in Spark Therapeutics by 14.0% in the second quarter. Teacher Retirement System of Texas now owns 2,432 shares of the company’s stock valued at $124,000 after buying an additional 299 shares during the last quarter. Legal & General Group Plc increased its position in Spark Therapeutics by 105.6% in the second quarter. Legal & General Group Plc now owns 2,714 shares of the company’s stock valued at $138,000 after buying an additional 1,394 shares during the last quarter. BlackRock Group LTD increased its position in Spark Therapeutics by 92.6% in the first quarter. BlackRock Group LTD now owns 4,843 shares of the company’s stock valued at $143,000 after buying an additional 2,328 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY increased its position in Spark Therapeutics by 46.0% in the first quarter. Metropolitan Life Insurance Co. NY now owns 7,823 shares of the company’s stock valued at $231,000 after buying an additional 2,465 shares during the last quarter. Hedge funds and other institutional investors own 78.79% of the company’s stock.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).

5 Day Chart for NASDAQ:ONCE

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.